| Literature DB >> 27863381 |
Huaying Fu1, Guangping Li1, Changle Liu1, Jian Li1, Lijun Cheng1, Wansong Yang1, Gary Tse2,3, Jichao Zhao4, Tong Liu1.
Abstract
Diabetes mellitus (DM) increases the risk of developing atrial fibrillation (AF), but the molecular mechanisms of diabetes-induced atrial remodeling processes have not been fully characterized. The aim of this study was to examine the mechanisms underlying atrial ion channel remodeling in alloxan-induced diabetes model in rabbits. A total of 40 Japanese rabbits were randomly assigned to a control group (C), alloxan-induced diabetic group (DM), probucol-treated control group (Control-P), and probucol-treated diabetic group (DM-P). Using whole-cell voltage-clamp techniques, ICa,L, INa and action potential durations (APDs) were measured in cardiomyocytes isolated from the left atria in the four groups, respectively. In the DM group, increased Ica,L and decreased INa currents were reflected in prolonged APD90 and APD50 values. These changes were reversed in the DM-P group. In conclusion, probucol cured AF by alleviating the ion channel remodeling of atrial myocytes in the setting of diabetes and the promising therapeutic potential of anti-oxidative compounds in the treatment of AF warrants further study.Entities:
Keywords: Pathology Section; alloxan-induced diabetes; atrial fibrillation; atrial ionic remodeling; calcium current; diabetes mellitus
Mesh:
Substances:
Year: 2016 PMID: 27863381 PMCID: PMC5356629 DOI: 10.18632/oncotarget.13339
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Biochemical and oxidative stress parameters
| Control group ( | DM group ( | DM-P group ( | control-P group ( | |
|---|---|---|---|---|
| Weight, Kg | 2.19±0.17 | 2.29±0.47 | 2.29±0.20 | 2.34±0.08 |
| Glu level at 8W,mmol/L | 5.58± 0.75 | 20.86±4.37 | 19.28±8.82 | 6.54±0.52 |
| BUN, mmol/L | 5.65±2.00 | 6.87±2.23 | 5.08±1.01 | 4.49±1.40 |
| Cr, umol/L | 98.5±16.31 | 103.7±29.22 | 95.13±27.18 | 89.66±9.48 |
| TG, mmol/L | 1.19±0.31 | 1.52±1.23 | 1.30±0.29 | 1.25±0.38 |
| TC, mmol/L | 1.14±0.57 | 1.25±0.39 | 0.87±0.35 | 0.92±0.36 |
| HDL-c, mmol/L | 0.56±0.16 | 0.49±0.20 | 0.43±0.14 | 0.47±0.17 |
| LDL-c, mmol/L | 0.36±0.16 | 0.38±0.16 | 0.31±0.15 | 0.24±0.10 |
| INS, uIU/ml | 16.24±7.87 | 5.71±3.01 | 7.33±1.56 | 13.89±5.11 |
| Serum CAT, U/ml | 6.40±2.46 | 4.79±2.06 | 4.80±0.96 | 5.35±1.74 |
| Serum SOD, U/ml | 588.08±82.09 | 556.29±47.7 | 589.18±63.44 | 640.12±82.02 |
| Serum MPO, U/L | 63.66±29.44 | 76.41±27.02 | 56.66±20.58 | 64.30±14.35 |
| Serum MDA, nmol/ml | 17.69±3.59 | 22.17±4.15 | 18.32±1.63 | 18.14±2.62 |
| CAT in atrium, U/mg prot | 4.30±1.29 | 3.82±1.87 | 4.00±1.13 | 4.78±1.33 |
| SOD in atrium, U/mg prot | 98.41±12.07 | 72.11± 11.08 | 88.48±8.81 | 93.03±20.04 |
| MPO in atrium, U/mg prot | 0.51±0.13 | 1.00±0.38 | 0.78±0.08 | 0.55±0.91 |
| MDA in atrium, mol/mg prot | 0.78±0.12 | 1.10±0.24 | 0.84±0.32 | 0.64±0.17 |
Values are mean ± SD; Abbreviations: LA-left atrial; LV-left ventricular;
Compared with Control group p < 0.05;
Compared with DM group p < 0.05
Figure 1A. representative INa evoked by the applied protocol; B. INa densities and peak INa density as a function of test potential; C. The steady-state activation curve of INa; D. The steady-state inactivation curve of INa, V1/2inact, TP: Test potential.
The shifts in activation and inactivation variables of INa (x±s)
| Group | Control | DM | DM-P | Control-P |
|---|---|---|---|---|
| 1.49±0.37 | 2.03±0.69 | 1.98±0.28 | 2.63±0.34 | |
| V1/2 (mV) | -56.97±0.78 | -57.01±1.12 | -54.48±0.74 | -52.93±0.48 |
| V1/2inact(mV) | 5.53±0.52 | 5.20±0.59 | 4.38±0.42 | 4.33±0.31 |
| -84.00±0.57 | -77.91±0.70 | -77.32±0.49 | -86.86±0.35 |
V1/2act (membrane voltage [Vm] at which half-activation occurs;V1/2inact: Vm at which half-inactivation occurs; k: the activation slope factor; kinact: inactivation slope factor
Figure 2A. representative IcaL evoked by the applied protocol; B. IcaL densities and peak IcaL density as a function of test potential, TP: Test potential; C. The steady-state activation curve of IcaL. TP: Test potential; D. Rate-dependent APD90 changes.
Figure 3Action potential recordings from representative cells obtained from a
A. control group; B. DM group; C. DM-P group and D. Control-P group. Action potentials were recorded in current-clamp mode at the frequencies indicated.
Mean values of APD90 and APD50(x±s)
| Control ( | DM( | DM-P ( | Control-P( | |
|---|---|---|---|---|
| RP(mv) | -78.41±6.04 | -77.70±6.20 | -74.26±6.94 | -74.14±5.28 |
| APD90-1Hz | 105.69±29.77 | 194.34±45.47 | 149.75±52.24 | 110.93±23.37 |
| APD90-2Hz | 102.34±26.39 | 191.19±42.04 | 138.62±48.76 | 98.08±30.55 |
| APD90-3Hz | 96.92±25.01 | 182.40±40.93 | 127.25±43.13 | 92.95±30.41 |
| APD90-4Hz | 91.38±23.33 | 158.28±16.09 | 114.11±35.16 | 81.95±26.03 |
| APD90-5Hz | 88.27±22.2 | 132.21±11.62 | 98.51±25.32 | 73.62±25.11 |
| APD50-1Hz | 35.26±20.34 | 69.65±24.02 | 70.22±35.90 | 44.50±11.53 |
| APD50-2Hz | 29.80±13.57 | 64.10±20.15 | 57.71±25.89 | 35.21±13.17 |
| APD50-3Hz | 27.97±8.14 | 182.40±40.93 | 46.32±12.04 | 30.26±10.76 |
| APD50-4Hz | 24.50±6.23 | 63.05±28.62 | 44.63±12.39 | 24.27±11.23 |
| APD50-5Hz | 20.51±5.15 | 55.83±28.40 | 37.62±9.59 | 22.06±10.68 |
| AP-amplitude(mv) | 204.96±20.14 | 134.54±24.58 | 134.69±14.01 | 188.85±14.79 |
| APA (mV) | 204.96±20.14 | 134.54±24.58 | 134.69±14.01 | 188.85±14.79 |
| Vmax (V/s) | 81.44±7.42 | 42.37±10.64 | 52.23±9.39* | 82.31±7.74 |
Abbreviations: RP: resting potential ;APA: action potential amplitude; Vmax: maximum rate of rise of the action potential; APD50, APD90: action potential duration at 50 and 90% repolarization;
Compared with Control group P < 0.05;
Compared with DM group P < 0.05